ArticleJournal of clinical microbiology2026
Performance of the LIAISON PLEX gram-negative blood culture assay for identifying bacterial pathogens and resistance genes in blood cultures.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gram-negative bacteria cause potentially life-threatening bloodstream infections worldwide. Delayed initiation of optimal antimicrobial therapy worsens health outcomes. Molecular assays characterize bloodstream pathogens and their antimicrobial resistance (AMR) genes faster than gold-standard culture-based methods. This multi-site study evaluated the performance of the automated multiplex LIAISON PLEX Gram-Negative Blood Culture (BCN) Assay (Luminex Corporation), which tests positive blood cultures for 19 gram-negative bacteria and 8 AMR genes, in approximately 2 h. Samples included 351 prospectively collected, 231 pre-selected, and 746 contrived specimens. For combined prospective plus pre-selected specimens, sensitivity/positive percent agreement was 90.0%-100% for 18/19 on-panel bacterial targets, and 97.8%-100% for detected AMRs. Specificity/negative percent agreement was ≥99.3% for all 19 bacterial targets, and ≥99.6% for AMRs. Common pathogens in prospective samples were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.